top of page
Untitled design_edited.jpg


Individuals currently infected with COVID-19 may be eligible for treatment with Tempol
era logo (3).png
Participant Enrollment Criteria
  • Have a laboratory confirmed infection of SARS-CoV-2 within the last 5 days

  • Have at least moderate severity of at least two COVID-19 symptoms (e.g., stuffy
    or runny nose, sore throat, fever, chills or shivers, difficulty breathing, coughing,
    headache, tiredness, muscle aches and pains, or nausea)

  • Be 18 years of age or older with at least one existing condition (hypertension,
    diabetes, obesity, cancer, chronic renal disease, or immunodeficiency)

  • Be able to travel to a clinic and be able to swallow a capsule

  • Additional criteria may apply

Participants Will Receive
  • Up to $700

  • Study treatment with either Tempol or placebo. 

  • Study-related medical evaluations

Location and Time
  • 7 total study visits over the course of 6 weeks at Eastside Research Associates in Redmond, WA 

The study will evaluate if early treatment with Tempol might prevent serious illness and hospitalization in high-risk people who are diagnosed with COVID-19.

What is Tempol?
  • Tempol is a unique antioxidant and anti-inflammatory medication that has been
    shown to attenuate Acute Respiratory Distress Syndrome in the lungs and decrease
    associated inflammatory cytokines (cytokine storm) associated with COVID-19.

  • Tempol was originally studied by the National Cancer Institute as a drug to provide
    protection to certain body organs during radiation therapy for cancer.

  • It has been studied extensively in animals and has already been shown to be safe in multiple human clinical studies.

  • Because of Tempol’s mechanism of action, it may also prevent viral replication of the COVID-19 virus, regardless of the variant.

  • In this study, Tempol is provided as a capsule that is taken by mouth. Two capsules will be taken twice per day, once in the morning before a meal and again in the evening before a meal

What does the study involve?

Participation in the study will last for up to 60 days.

If you qualify for the study, you will begin receiving study treatment with either Tempol or placebo. Placebo is an inactive substance that helps us better understand the effects of the investigational drug. You will attend about 6 study visits over the next month to collect blood and urine samples and to check on your health. You will take the study treatment twice each day for the first 2 weeks during this period. About 6 weeks later you will have 1 final follow-up visit to check on your health.

During the study, you will use an e-diary, which is an app you will download to your own smartphone/device, to keep track of your symptoms, study treatment dosing, and to answer questions about your health. You will also be provided with a thermometer for checking your body temperature and a pulse oximeter (a small fingertip sensor that measures the oxygen level in your blood).


If you are interested in participating in this study or have questions about your eligibility, please use the form below or contact the study coordinator.

Rana Yavarzadeh  - Clinical Research Coordinator 

(425) 869-6828

Sign Up to Participate in the COVID-19 Treatment Study

Which of the following describes your current illness?
Have you received one or more dose of a COVID-19 vaccine?
Have you had a previously documented infection with COVID-19?

Join our participant list for future studies.

Please fill out the following form to join our participant list for current and future studies. A member of our study recruitment team will receive your information and reach out to you within one business day.

bottom of page